000 03232nam a22004335i 4500
001 60319
005 20200226102446.0
007 cr nn 008mamaa
008 170325s2017 gw | s |||| 0|eng d
020 _a9783319509563
_9978-3-319-50956-3
024 7 _a10.1007/978-3-319-50956-3
_2doi
035 _a(DE-He213)978-3-319-50956-3
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
245 1 0 _aLiquid Biopsies in Solid Tumors
_h[electronic resource] /
_cedited by Massimo Cristofanilli.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Humana Press,
_c2017.
300 _aX, 161 p. 14 illus., 12 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development,
_x2196-9906
505 0 _a1.Blood-based diagnostics in solid tumors: an overview -- 2.Circulating tumor cells (CTCs) in primary disease: the seed for metastasis -- 3.Enumeration and molecular analysis of CTCs in metastatic disease: The breast cancer model -- 4.Epithelial-Mesenchymal Transition (EMT) and cancer stem cells (CSCs): The traveling metastasis -- 5.Detection and monitoring of circulating immune cells in solid tumors: shifting priorities -- 6.Circulating-free tumor DNA (ctDNA): the real-time liquid biopsy -- 7.CTCs and ctDNA: two tales of a complex biology -- 8.Exosome: decoding the messaging system.
520 _aThis volume, with chapters written by experts in the field of cancerous tumors, details the key factors associated with liquid biopsies in solid tumors: blood-based diagnostics; circulating tumor cells; enumeration and molecular analysis (association with breast cancer); epithelialmesenchymal transition; detection and monitoring; circulating-free tumor DNA; CTCs and ctDNA; and the exosome. The field of blood-based diagnostics is rapidly evolving demonstrating the possibility of real-time molecular analysis of cancer cells and their phenotype and genotype. Circulating Tumor Cell (CTCs) have demonstrated prognostic and predictive value in advanced cancer and represents a source of tumor cells for transcriptome and genomic analysis. Most recently, the detection of genomic abnormalities in the peripheral blood by sensitive and selective PCR methods (liquid biopsy) opened to the option of a comprehensive blood-based tumor analysis. Similar information can be obtained by analysis of exosome, a natural packaging and messaging system being explored in advanced malignancies. The final frontier is the evaluation of immune cells determinant of innate and adaptive immunity.
650 0 _aMedicine.
650 0 _aCancer research.
650 1 4 _aBiomedicine.
650 2 4 _aCancer research.
700 1 _aCristofanilli, Massimo.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783319509556
830 0 _aCancer Drug Discovery and Development,
_x2196-9906
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-319-50956-3
912 _aZDB-2-SME
999 _c4775
_d4775